Aug 17, 2022 7:25am EDT Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
Jul 11, 2022 7:00am EDT Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
Jun 29, 2022 7:00am EDT Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
Jun 24, 2022 7:00am EDT Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
Jun 09, 2022 7:00am EDT Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
May 26, 2022 7:00am EDT Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
May 02, 2022 7:00am EDT Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
Apr 05, 2022 7:00am EDT Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
Mar 28, 2022 7:00am EDT Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
